Missense mutations in LRRK2 were first identified as a cause of Parkinson’s disease (PD) in 2004. Subsequent studies showed that these mutations account for up to 10 percent of familial cases, with ...

This database is a repository of normal genetic variability, designed to be a tool for researchers who study neurodegenerative disease. It contains whole-exome sequencing results from nearly 500 ...

Dennis Selkoe Co-Director, Brigham and Women's Hospital's Ann Romney Center for Neurologic Diseases; Posted: 21 Mar 2019 This morning’s news that an interim analysis by Biogen of their Phase 3 ...

It has been clear for a while that anti-amyloid antibodies can sweep plaque from the brain, but until now the question of whether this slows cognitive decline has remained hotly contended. Despite ...

28 Sep 2022. Eisai and Biogen yesterday announced positive topline results from the Phase 3 Clarity trial of their anti-amyloid antibody lecanemab.The drug slowed decline on the primary endpoint, ...

Takaomi Saido RIKEN Center for Brain Science; Posted: 21 Nov 2022 There seems to be some misunderstanding about our App (Saito et al., 2014; Watamura et al., 2022), MAPT (Hashimoto et al., 2019), and ...

20 Jan 2022. After months of uncertainty, the hammer fell for Biogen: In a draft decision released January 11, the Centers for Medicare and Medicaid Services proposed to cover the anti-amyloid ...

Dennis Selkoe Co-Director, Brigham and Women's Hospital's Ann Romney Center for Neurologic Diseases; Posted: 11 Nov 2020 The negative vote on Biogen’s aducanumab filing by the FDA Advisory Committee ...

04 May 2023. Score another one for amyloid immunotherapy. The anti-pyroglutamated amyloid antibody donanemab has posted positive top-line results in the Phase 3 Trailblazer-Alz2 study, according to an ...

22 Mar 2024. Old drugs die hard. Despite a string of negative Phase 3 trials, HMTM, a derivative of the malaria drug methylene blue, resurfaced again at AD/PD 2024, held March 5-9 in Lisbon, ...

Scientists the world over are shocked and saddened to learn that John Q. Trojanowski passed away on February 8, at the altogether too-young age of 75. The cheerful and unmovable object to the ...

In 2015, the Amyloid Biomarker Study published two separate meta-analyses of amyloid prevalence. In one, the researchers combined data from 91 studies that measured amyloid in more than 7,500 people ...